3D Bioprinting Market Will Generate New Growth Opportunities By 2027

The Global 3D Bioprinting Market by Component (3D Bioprinters (Microextrusion, Inkjet, Laser, Magnetic), Bioink (Natural, Synthetic, Hybrid)), Material(Hydrogel, Living Cells), Application (Research, Clinical), End user (Biopharma, Academia) – Global Forecast to 2027” The global 3D Bioprinting Market is projected to USD 3.3 billion by 2027 from USD 1.3 billion in 2022, at a CAGR of 20.8% between 2022 and 2027. Factors such as technological advancements in 3D bioprinters and biomaterials, increasing use of 3D bioprinting in the pharmaceutical and cosmetology industries, and rising public and private funding to support bioprinting research activities drive the market growth. However, factors like dearth of skilled professionals and high development and production costs are restraining the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170201787

Browse in-depth TOC on “3D Bioprinting Market”

297 – Tables

38 – Figures

270 – Pages

Key Player

Key players in the global 3D Bioprinting Market include BICO Group AB (US), Organovo Holdings Inc. (US), Allevi, Inc. (part of 3D Systems, Inc.) (US), CollPlant Biotechnologies Ltd. (Israel), regenHU (Switzerland), EnvisionTEC GmbH (part of Desktop Metal, Inc.) (Germany), Aspect Biosystems Ltd. (Canada), Advanced Solutions Life Sciences, LLC (US), and Regenovo Biotechnology Co., Ltd. (part of Shining 3D Tech Co., Ltd.) (China).

BICO Group AB (US) offers products for 3D cell cultures for high-throughput drug screening and printing of human tissues and organs. The company’s clients include the medical, pharmaceutical, and cosmetic industries. The company operates in two broad business segments, namely, Laboratory Solutions and Bioautomation (Industrial Solutions segment till 2020). The company has a strong geographic footprint with 14 subsidiaries and a global presence spanning North America, Europe, Latin America, and the Asia Pacific. From 2019 to 2021, the company has engaged in strategic developments such as acquisitions, product launches, and geographic expansions. Thus, the company is expected to witness significant growth in the global 3D bioprinting market.

3D Systems, Inc. (US) acquired Allevi, Inc. in 2021. The company develops and commercializes 3D tissues for use in the healthcare industry through Allevi. The company’s products include 3D bioprinters, bioinks, and software, which assist in the layer-by-layer printing of 3D living tissues. The company also specializes in regenerative medicine, tissue engineering, 3D bioprinting, and 3D printing. 3D Systems develops innovative 3D bioprinting solutions to maintain its dominant position in the 3D bioprinting market. For instance, in June 2021, 3D Systems, along with CollPlant, developed a 3D-bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. The company’s increased focus on research and development activities and strengthening its geographic presence are expected to facilitate its growth in the 3D bioprinting market.

Enquiry Before Buying this Report:


Drivers: Increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries:

The increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries has been a major driver of the market. 3D bioprinting enables the production of complex 3D structures, which are difficult to produce using traditional methods. This has enabled the production of complex drug molecules and formulations, as well as cosmetic products such as artificial skin, hair follicles, and other tissues. The increasing demand for 3D bioprinted products in the pharmaceutical and cosmetic industries has been a major driver of the market.

Opportunities: Rising demand for organ transplants:

3D bioprinting is a rapidly growing field in the medical industry. It is a process of creating living tissues and organs from a computer aided design model. This technology has the potential to revolutionize the way medical treatments are done. 3D bioprinting has the potential to address the ever increasing demand for organ transplants, which is currently outstripping the available donor organs. This technology can provide an ethical and efficient approach to creating organs for transplant. Additionally, 3D bioprinting has the potential to reduce costs associated with organ transplants. As the technology continues to improve, the market for 3D bioprinting is expected to grow significantly in the coming years.

Challenges: Process control and understanding of 3D bioprinters

One of the major challenges in the market is the process control and understanding of 3D bioprinters. The 3D bioprinters require precise control over the material and process parameters, such as temperature, pressure, and composition of the material being printed. Due to the complexity of the process, it can be difficult to understand and control the bioprinting process. This can lead to inaccurate results and potential damage to the printed material. To address this challenge, 3D bioprinting companies have developed dedicated software that can help manage the printing process and optimize its settings. Additionally, the use of automated process control systems can help ensure more consistent results. Additionally, research is being conducted to improve the understanding of the 3D bioprinting process and develop improved bioprinting materials.

The 3D Bioprinters segment accounted for the largest share in the 3D Bioprinting market, by component, during the forecast period.

Based on component, the 3D bioprinting market is segmented into 3D bioprinters and bioinks. 3D bioprinters accounted for the larger market share in 2021. Technological advancements and the growing demand for organ transplants are the major factors driving the growth of this segment.

The Research applications subsegment accounted for the largest share of the application segment in the 3D Bioprinting market in 2021.

Based on application, the 3D bioprinting market is segmented into research applications and clinical applications. The research applications segment accounted for the larger share of the 3D bioprinting market in 2021. The market for research applications is further segmented into drug research, regenerative medicine, and 3D cell culture. Among these, the drug research segment accounted for the largest share of the market in 2021, due to the growing adoption of 3D bioprinting technology by biopharmaceutical companies.

The Research Organizations and Academic Institutes subsegment accounted for the largest share of the application segment in the 3D bioprinting market in 2021.

On the basis of end users, the 3D bioprinting market is segmented into research organizations and academic institutes, biopharmaceutical companies, and hospitals. Research organizations and academic institutes form the largest and fastest-growing end-user segment in this market. This can be attributed to the increasing collaborations between academic & research institutes and key market players for developing novel 3D-bioprinted products.

 North America is the largest region and Asia Pacific is the fastest-growing region of the 3D Bioprinting market in 2021.

Based on region, the 3D bioprinting market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America dominated the market, followed by Europe. The significant government and private investments to develop advanced 3D bioprinting technologies, the high adoption rate of these technologies, and the presence of key market players in the region are responsible for the large share of North America in the 3D bioprinting market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=170201787

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/3d-bioprinting-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/3d-bioprinting.asp

Our Other Reports: